<DOC>
	<DOC>NCT02077036</DOC>
	<brief_summary>The overall aim of the study is to investigate the effect of a new, non-pharmacological method that may alleviate the symptoms of narcolepsy and thereby lead to a reduction in the use of medications with potentially serious side effects in patients with this disease.</brief_summary>
	<brief_title>Narcolepsy - New Potential Treatment</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<criteria>Signed informed consent Diagnosed with narcolepsy (diagnose code G47.4) 16 60 years of age MSLT has shown hypersomnia (sleeping latency &lt; 8 min) &amp; 1 episode REM HLAtype associated with increased occurrence of narcolepsy Reduced cognitive function Other relevant organ disease (that could affect the study results or put the patient at risk) Ongoing bacterial infection in the nose Comorbidity that can increase the risk of bleeding Has received treatment with an implantable stimulator or other implantable product in the head and / or in the neck Known pronounced septal deviation Known allergy to polyvinylchloride or medicinal liquid paraffin Women not using adequate contraceptives Participated in a clinical investigational drug trial within the previous 30 days</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>